AR099820A1 - Ciano que contiene compuestos de azabenzofuran para el tratamiento de la hepatitis c - Google Patents
Ciano que contiene compuestos de azabenzofuran para el tratamiento de la hepatitis cInfo
- Publication number
- AR099820A1 AR099820A1 ARP150100859A ARP150100859A AR099820A1 AR 099820 A1 AR099820 A1 AR 099820A1 AR P150100859 A ARP150100859 A AR P150100859A AR P150100859 A ARP150100859 A AR P150100859A AR 099820 A1 AR099820 A1 AR 099820A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- compounds
- substituted
- fluoro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical class N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 150000002431 hydrogen Chemical group 0.000 abstract 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 4
- 241000711549 Hepacivirus C Species 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos, que incluyen sus sales, además de composiciones y métodos para usar los compuestos. Los compuestos tienen actividad contra el virus de la hepatitis C (HCV) y pueden ser útiles en el tratamiento de los pacientes infectados con HCV. Reivindicación 1: Un compuesto caracterizado por la fórmula (1), que incluye sales de este aceptables desde el punto de vista farmacéutico, en donde Z es C-R⁵ o N; R⁰ es hidrógeno; R¹ es metilo; R² es fenilo que se sustituye independientemente con 0 - 2 halo o metoxi, o es para sustituido con W-Ar; W es -O- o -NH-; Ar es fenilo o para-halofenilo; R³ es hidrógeno, fluoro o cloro; R⁴, R⁵, y R⁶ se seleccionan independientemente del grupo de hidrógeno, halo, alquilo, haloalquilo, alcoxi y perdeuteroalcoxi; R⁷ᵃ, R⁷ᵇ se seleccionan, cada uno independientemente, del grupo de hidrógeno, alquilo, cicloalquilo, y Ar¹ o juntos R⁷ᵃ y R⁷ᵇ forman un anillo carbocíclico de 3 - 7 miembros; R⁸ es hidrógeno, Ar¹ es fenilo, un anillo heteroaromático de 5 miembros o un anillo heteroaromático de 6 miembros; R⁹ es hidrógeno, halo, R²⁰¹, OR²⁰², NR²⁰³R²⁰⁴; R²⁰¹ es alquilo, alquenilo o C₁₋₄ alquilo con entre uno y todos los hidrógenos reemplazados por fluoro; R²⁰² es C₁₋₃ alquilo o C₁₋₃ alquilo con entre uno y todos los hidrógenos reemplazados por fluoro; R²⁰³ es hidrógeno; y R²⁰⁴ es C₁₋₃ alquilo o C₁₋₃ hidroxialquilo o es C₁₋₃ alquilo con entre uno y todos los hidrógenos reemplazados por fluoro.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461968763P | 2014-03-21 | 2014-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099820A1 true AR099820A1 (es) | 2016-08-17 |
Family
ID=52808191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100859A AR099820A1 (es) | 2014-03-21 | 2015-03-20 | Ciano que contiene compuestos de azabenzofuran para el tratamiento de la hepatitis c |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9249152B2 (es) |
| EP (1) | EP3119785B1 (es) |
| JP (1) | JP2017509700A (es) |
| KR (1) | KR20160126085A (es) |
| CN (1) | CN106459070A (es) |
| AR (1) | AR099820A1 (es) |
| AU (1) | AU2015231139A1 (es) |
| CA (1) | CA2943526A1 (es) |
| CL (1) | CL2016002361A1 (es) |
| EA (1) | EA201691777A1 (es) |
| ES (1) | ES2688554T3 (es) |
| IL (1) | IL247830A0 (es) |
| MX (1) | MX2016012104A (es) |
| PE (1) | PE20161224A1 (es) |
| SG (1) | SG11201607750PA (es) |
| TW (1) | TW201620914A (es) |
| WO (1) | WO2015143255A1 (es) |
| ZA (1) | ZA201606478B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015143256A1 (en) * | 2014-03-21 | 2015-09-24 | Bristol-Myers Squibb Company | Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis c |
| KR20180086247A (ko) * | 2015-12-07 | 2018-07-30 | 플렉시콘 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법과 이들에 대한 징후 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050065661A (ko) | 2002-11-01 | 2005-06-29 | 비로파마 인코포레이티드 | 벤조푸란 화합물, 조성물 및 ｃ형 간염 바이러스 감염 및관련 질병의 치료 및 예방 방법 |
| MX2010004623A (es) | 2008-02-14 | 2010-06-07 | Hoffmann La Roche | Compuestos heterociclicos antiviricos. |
| US8048887B2 (en) * | 2008-09-11 | 2011-11-01 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7994171B2 (en) * | 2008-09-11 | 2011-08-09 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8198449B2 (en) * | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| JP5572725B2 (ja) | 2010-03-10 | 2014-08-13 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎の処置のための化合物 |
| PH12013500770A1 (en) | 2010-10-26 | 2018-01-17 | Presidio Pharmaceuticals Inc | Inhibitors of hepatitis c virus |
-
2015
- 2015-03-20 EP EP15714137.5A patent/EP3119785B1/en not_active Not-in-force
- 2015-03-20 AU AU2015231139A patent/AU2015231139A1/en not_active Abandoned
- 2015-03-20 EA EA201691777A patent/EA201691777A1/ru unknown
- 2015-03-20 JP JP2017501122A patent/JP2017509700A/ja active Pending
- 2015-03-20 AR ARP150100859A patent/AR099820A1/es unknown
- 2015-03-20 CA CA2943526A patent/CA2943526A1/en not_active Abandoned
- 2015-03-20 SG SG11201607750PA patent/SG11201607750PA/en unknown
- 2015-03-20 TW TW104109071A patent/TW201620914A/zh unknown
- 2015-03-20 PE PE2016001648A patent/PE20161224A1/es not_active Application Discontinuation
- 2015-03-20 US US14/663,497 patent/US9249152B2/en active Active
- 2015-03-20 CN CN201580024715.3A patent/CN106459070A/zh active Pending
- 2015-03-20 ES ES15714137.5T patent/ES2688554T3/es active Active
- 2015-03-20 KR KR1020167028891A patent/KR20160126085A/ko not_active Withdrawn
- 2015-03-20 MX MX2016012104A patent/MX2016012104A/es unknown
- 2015-03-20 WO PCT/US2015/021638 patent/WO2015143255A1/en not_active Ceased
-
2016
- 2016-09-15 IL IL247830A patent/IL247830A0/en unknown
- 2016-09-20 CL CL2016002361A patent/CL2016002361A1/es unknown
- 2016-09-20 ZA ZA2016/06478A patent/ZA201606478B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2016002361A1 (es) | 2017-04-21 |
| WO2015143255A1 (en) | 2015-09-24 |
| US20150266886A1 (en) | 2015-09-24 |
| EP3119785A1 (en) | 2017-01-25 |
| IL247830A0 (en) | 2016-11-30 |
| EA201691777A1 (ru) | 2016-12-30 |
| CN106459070A (zh) | 2017-02-22 |
| TW201620914A (zh) | 2016-06-16 |
| JP2017509700A (ja) | 2017-04-06 |
| MX2016012104A (es) | 2016-12-09 |
| CA2943526A1 (en) | 2015-09-24 |
| US9249152B2 (en) | 2016-02-02 |
| PE20161224A1 (es) | 2016-11-12 |
| AU2015231139A1 (en) | 2016-11-03 |
| ES2688554T3 (es) | 2018-11-05 |
| KR20160126085A (ko) | 2016-11-01 |
| SG11201607750PA (en) | 2016-10-28 |
| ZA201606478B (en) | 2018-05-30 |
| EP3119785B1 (en) | 2018-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR115662A2 (es) | Derivados de piperidina | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR093818A1 (es) | Compuesto de 1-(bencil sustituido)piperazina sustituida | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| AR085327A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR094537A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa | |
| AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR094300A1 (es) | Derivados de quinolonas | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR099495A1 (es) | Derivados de amida, antagonistas de orexina | |
| AR093758A1 (es) | Inhibidores de aril lactama quinasa | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR104512A1 (es) | Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |